The Preclinical Tumor Analysis and Imaging (PTAI) Shared Resource is dedicated to facilitating in vivo studies of tumors by Cancer Center members. This Shared Resource serves to move research projects from the bench or from a patient's sample into an in vivo animal model context, thereby enhancing the translation of discoveries into useful knowledge for potential therapeutic applications. PTAI was formed by merging the pre-existing Molecular Assessment and Preclinical Studies (MAPS) shared resource with the Animal Imaging Shared Resource, so as to better integrate imaging into analyses of animal tumor models. The PTAI Shared Resource tests therapies involving small molecules, biologies, and/or radiation in a variety of tumor models and also helps translational investigators generate these models. This resource offers guidance and assistance for the design and performance of standardized or customized protocols for subcutaneous and orthotropic xenograft and syngenic mouse models. The PTAI Shared Resource uses ACUC approved protocols to perform preclinical studies, can follow established protocols, and will help investigators design custom protocols. New emphasis is placed on the noninvasive detection and measurement of tumor growth and spread using bioluminescence, PET or MRI. Staff members have considerable experience and serve as consultants and trainers as well as service providers. They also act as agents to coordinate services in other shared resources, providing a single point of contact for a PI to carry out an entire study that might include culture of cells, immunohistochemistry, flow cytometry, molecular analyses of tumors, and statistics. The PTAI provides laboratory services to clinicians, some of whom may not have appropriate laboratory facilities or staff, and initiates animal studies for laboratory scientists who have inadequate experience with in vivo models and otherwise depend solely on in vitro models. The advantages provided by in vivo preclinical studies include the development of whole animal model systems for 1) drug response predictions in human patients and analysis of mechanisms, 2) depicting the heterogeneity of human tumor cells, the complexity of which cannot be obtained within the confines of in vitro studies;3) mimicking the tumor microenvironment and 4) tracking the progression, spread and invasion of metastatic cancers. The services offered by PTAI are an integral part of the Cancer Center translational research initiatives.

Public Health Relevance

The PTAI provides the tools that link mouse models to human tissues, and is a critical facilitator of translational research. It enables basic scienfists to do animal experiments and clinical scientists to access lab techniques.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-23
Application #
8635296
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
23
Fiscal Year
2014
Total Cost
$69,270
Indirect Cost
$29,102
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815
Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429
Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117

Showing the most recent 10 out of 539 publications